ZymoGenetics builds cash reserves as it advances Thrombin

Seattle-based ZymoGenetics has added $125 million to its cash reserves, bringing total cash on hand to about $400 million. Company execs say that much of the money will go to a late-stage trial of Thrombin, an experimental drug to control bleeding during surgery. The funds will also help bankroll the creation of a 50-man sales force that will be assembled to market Thrombin once it receives FDA approval.

- read this article in the Seattle Post-Intelligencer for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.